Table 2. Summary of PHEN’s activity against cancer and metastasis.

Reference	Findings
Nelson, 2015 64	PHEN at clinically achievable concentration reduces breast cancer growth, invasion and metastasis in vivo in a xenograft model.
Yang M, 2012 60	At clinically achievable concentration PHEN inhibited migration and invasion of highly metastatic breast cancer MDA-MB-231 cell line, and had no effect on MCF-7 cell line which has a low metastatic potential and do not express VGSCs.
Lee Ts, 2010 65	DPTH-N10 a phenytoin derivate drug, inhibits proliferation of COLO 205 colon cancer cell line.
Lyu Y, 2008 66	DPTH-N10 a phenytoin derivate drug, shows strong anti-angiogenic activity. Inhibits HUVEC proliferation and capillary like tube formation.
Sikes, 2003 67	New VGSC blockers based on PHEN, showed increased inhibition of prostate cancer growth.
Anderson, 2003 68	Developed new VGSC blockers based on the PHEN binding site study. These new VGSC blockers showed potent inhibition of prostate cancer cells growth (Androgen independent PC3 line).
Fraser, 2003 36	PHEN decreased motility of prostate cancer cells.
Abdul, 2001 62	PHEN and carbamazepine decreased PSA secretion in human prostate carcinoma cell lines.
Lobert, 1999 69	PHEN has inhibitory effects on microtubule assembly and has additive effects with vinblastine.
Kawamura, 1996 70	PHEN potentiates vinblastine citotoxicity.
Sato K, 1994 31	PHEN decreased growth of MIA PaCa-2 (pancreatic cancer cells).
Lang DG, 1993 71	PHEN, Carbamazepine and lamotrigine are inhibitors of sodium channels and reduces glutamate release in rat neuroblastoma cells.
Tittle, 1992 72	PHEN decreased growth in six murine tumor cell lines of lymphoid origin.